

Drug Tracker is a special monthly feature summarising and analysing ADEC recommendations, PBAC outcomes and changes to PBS listings. In the July 2009 *Drug Tracker* we summarise the 1 July, 2009 PBS listings and conduct a trend analysis of the PBS listing status for those drugs that received a positive recommendation from the PBAC.

The Pretium database houses PBAC recommendations and PBS listings and ADEC recommendations from the dates that these data were made public. The database includes sponsor names, drug names, PBS codes, brand names, strength and types of drugs, ATC codes down to level 5 and additional product by product detail.

Access to this depth of data allows *Drug Tracker* to expose clear trends in how regulators and reimbursement authorities affect the process of bringing new drugs to market.

In the June issue of *Drug Tracker*, we presented notable PBS listings from the June 1, 2009 Schedule; ADEC recommendations from the April 2009 meeting; and conducted a trend analysis of the probability of success of PBAC submissions, stratified by submission type. In the period between June 2003 and March 2009, there were 351 major submissions, 585 minor submissions, 1 PBAC review and 2 independent reviews. There was also 1 for which the details were unknown. The data indicated that the probability of success for all initial submissions remains steady at approximately 80%. However, although the probability of success for a major initial PBAC submission varied greatly from meeting to meeting, the overall trend demonstrates a decreasing probability of success over this period.

July Summary

As indicated earlier, in this month's issue of *Drug Tracker*, we present notable PBS listings that occurred on July 1, 2009 and conduct a trend analysis of the PBS listing status for those drugs that received a positive recommendation from the PBAC.

There were only a small number of amendments to the July 1, 2009 Schedule of Pharmaceutical Benefits, including bevacizumab (**Avastin**[®]) for first-line treatment of metastatic colorectal cancer and etravirine (**Intelence**[®]) for the treatment of HIV infections.


Trends in PBS listing compared to PBAC approval

From a sample of 1,022 successful submissions to the PBAC over the period 2000 to 2008 inclusive, we examine the PBS status of these drugs and the change in the percentage listed over this period. In this period, there were 875 positive submissions that resulted in PBS listing and 147 that did not. Over the period 2000 – 2006 there were 703 successful submissions, and of these there were 633 positive submissions that resulted in PBS listing and 70 that did not – an average 10% where no PBS listing has occurred despite a positive recommendation from the PBAC. Over the period 2007 to 2008, this percentage has risen to 18 and 30%, respectively. The trend is displayed in **Figure 1**. This graph shows that the percentage of positive PBAC

recommendations with no subsequent PBS listing appears either to be increasing, or is evidence of prolonged delays by a number of drugs following the PBAC process that cannot be accounted for by a lack of cost effectiveness.

Figure 1 Percentage of PBAC approvals and PBS listing status

Percentage of PBAC approvals that do not yet have PBS listing



For more information on *Drug Tracker* or **Pretium's** data and services, contact Annette Kerr on 02 8088 1500 or email info@pretium.com.au.